$PHVS

Nijdam Anna sold $82K of PHVS

Nijdam Anna (Principal Accounting Officer) sold 2,670 shares of Pharvaris N.V. (PHVS) at $30.87 on 2026-06-04.

Original reporting
SEC EDGAR · Nijdam Anna
Published Jun 8, 2026, 6:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by a named officer, which can marginally affect sentiment but does not provide operational or financial guidance.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it is unlikely to drive a fundamental repricing alone.

03

What to watch

Check whether there are additional insider transactions around the same period and whether the insider’s remaining holdings materially change over subsequent filings.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-08)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

SEC Form 4 shows PHVS principal accounting officer Nijdam Anna sold 2,670 shares in an open-market transaction for ~$82.4K.

Expected impact

Low near-term impact; any effect is likely short-lived unless selling accelerates or coincides with other negative news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is a relatively small dollar amount and does not indicate a new company event (no guidance, trial, deal, or enforcement action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially with no 10b5-1 plan disclosed.

Key entities

  • Pharvaris N.V.

    Company whose insider transaction was reported on SEC Form 4.

  • Nijdam Anna

    Principal Accounting Officer who sold 2,670 PHVS shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.